About This Event

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, visits the Nasdaq MarketSite in Times Square to commemorate the historic first-ever approval of a CRISPR-based therapy and celebrate innovation as CRISPR Therapeutics continues to expand and advance its pipeline of programs for rare and common diseases.

In honor of the occasion, Samarth Kulkarni, PhD, Chief Executive Officer & Chairman of CRISPR Therapeutics, with members of the CRISPR Therapeutics team and Board of Directors, rings the Opening Bell.